Results 11 to 20 of about 10,082 (250)

Novel actionable ROS1::GIT2 fusion in non-Langerhans cell histiocytosis with central nervous system involvement [PDF]

open access: hybridActa Neuropathol, 2022
Gábor Bedics   +9 more
openalex   +2 more sources

Disseminated non-Langerhans cell histiocytosis with an IRF2BP2-NTRK1 gene fusion identified by next-generation sequencing [PDF]

open access: goldJAAD Case Rep, 2020
Warren Chan   +7 more
openalex   +2 more sources

Intracranial findings of Non-Langerhans-Cell Histiocytosis

open access: green, 2019
Learning objectives Background Findings and procedure details Conclusion Personal information ...
Renata Bertanha
openalex   +2 more sources

Erdheim- Chester Disease (Non-Langerhans Cell Histiocytosis)

open access: bronzeJournal of Cancer Research Reviews & Reports
52 years old female with recurrent admission for myalgias, inflammatory arthritis, rash around the eyes and abdomen (A, B). Routine blood tests were either normal or negative apart from low C4 level. Pan CT of the body was unremarkable.
Yousef Gulnaz, Adel Ekladious
openalex   +2 more sources

Non Langerhans Cell Histiocytosis of the Rectum: Case Report and Review of the Literature

open access: diamondJapanese Journal of Gastroenterology and Hepatology, 2022
Histiocytosis is a condition resulting from the abnormal proliferation of dentritic cells of the mononuclear phagocytic system. Previously classified as Langerhans cell histiocytosis and non-Langerhans cell histiocytosis, and recently into 5 categories (L, C, R, M and H), it can be localized to an organ or have a systemic manifestation, affecting most ...
Malek Michael Bouhairie   +3 more
openalex   +2 more sources

A RARE CASE OF PULMONARY NON-LANGERHANS CELL HISTIOCYTOSIS [PDF]

open access: bronzeChest, 2020
Victoria González   +3 more
openalex   +2 more sources

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis [PDF]

open access: goldBlood Adv, 2023
Ashley Aaroe   +12 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy